Introduction: In type 1 diabetes increased risk of severe hypoglycaemia is associated with high angiotensin-converting enzyme (ACE) activity. We tested in healthy humans the hypothesis that this association is explained by the reduced ability of subjects with high ACE activity to maintain normal cognitive function during hypoglycaemia. Methods: Sixteen healthy volunteers selected by either particularly high or low serum ACE activity were subjected to hypoglycaemia (plasma glucose 2.7 mmol/L). Cognitive function was assessed by choice reaction tests. Results: Despite a similar hypoglycaemic stimulus in the two groups, only the group with high ACE activity showed significant deterioration in cognitive performance during hypoglycaemia. In the high ACE group mean reaction time (MRT) in the most complex choice reaction task was prolonged and error rate (ER) was increased in contrast to the low ACE group. The total hypoglycaemic symptom response was greater in the high ACE group than in the low ACE group (p=0.031).There were no differences in responses of counterregulatory hormones or in concentrations of substrates between the groups. Conclusion: Healthy humans with high ACE activity are more susceptible to cognitive dysfunction and report higher symptom scores during mild hypoglycaemia than subjects with low ACE activity. Hanne Damm,
Introduction
Hypoglycaemia is the dominant side effect to insulin therapy in type 1 diabetes and represents a major barrier to achievement of optimal glycaemic control in many patients. 1 While some episodes are recognised and corrected by the patients many hypoglycaemic episodes remain unrecognised due to impaired awareness of hypoglycaemic warning symptoms. 2 During unrecognised hypoglycaemic episodes the ability to maintain cognitive function is important for the patients to continue their activities until the episodes are corrected by planned meals, waning of the insulin effect, or hormonal counterregulation. Impaired cognition may lead to severe hypoglycaemia with need for assistance from other persons to restore glucose levels. The highly variable interindividual risk of severe hypoglycaemia in type 1 diabetes that is only partly explained by hypoglycaemia awareness and hormonal counterregulatory capacity 3, 4 suggests clinically significant differences between subjects in the ability to maintain cognitive function during hypoglycaemia. The sparse knowledge about factors influencing cognition during hypoglycaemia is a major obstacle to the understanding and prevention of severe hypoglycaemia.
We and others previously reported an association between high spontaneous serum angiotensinconverting enzyme (ACE) activity and occurrence of severe hypoglycaemia in type 1 diabetes independent of hypoglycaemia awareness and other previously known risk factors. [5] [6] [7] [8] This finding led us to hypothesise that subjects with high ACE activity may have a reduced capability to maintain normal cognitive function during hypoglycaemia.
The aim of this study was to assess the relationship between ACE activity and cognitive function during hypoglycaemia and specifically to test the hypothesis that healthy subjects with high spontaneous ACE activity are more affected by hypoglycaemia in terms of cognitive dysfunction than subjects with low ACE activity. Moreover, we aimed at exploring associations between ACE activity and symptomatic and hormonal responses.
Research, design and methods Subjects
In a cohort of 53 healthy subjects recruited to a screening phase a venous blood sample was drawn for measurement of serum ACE activity and determination of ACE Insertion/Deletion genotype as described previously. 9 Those eight subjects with the highest and those eight with the lowest screening values of serum ACE activity (mean [range]: 52.3 and 20.4 [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] U/L) were selected to participate in the experiment. The characteristics of the subjects are shown in table 1. Subjects were instructed to live and eat as normally as possible and to avoid vigorous exercise, as well as the use of alcohol and drugs, in the week preceding the experiments. The study was approved by the regional Ethics Committee.
Design
The study was a randomised counterbalanced cross-over study between insulin and placebo with at least three weeks between sessions.
Subjects were blind to treatment and experimenters were blind to subjects' ACE status.
The purpose was to assess differences during experimentally induced hypoglycaemia between subjects with high or low ACE activity and such differences could potentially occur in every aspect of response to, or protection against, hypoglycaemia (degree of hypoglycaemia, 
Experimental protocol
On the day of experiment, subjects arrived at 7.30 a.m. in the laboratory after an overnight fast. Following careful introduction to the experimental setting and scheme, subjects were equipped as follows: 1) Electroencephalogram (EEG) cap and two precordial electrocardiogram (EKG) leads connected to a digital EEG recorder (Cadwell, Kennewick, Washington, USA); 2) head phones (in-ear type) connected to a computer delivering auditory stimuli; 3) ambulatory blood pressure (BP) monitoring unit (Bosch + Sohn, Jungingen, Germany); 4) intravenous cannula in an ante-cubital vein in the non-dominant forearm. Subsequently, subjects were introduced to the computerised cognitive function test, the California Computerised Assessment Package (CalCAP) (Miller and Norland Software, Los Angeles, California, USA); 10 the test was performed once to accustom subjects to the procedure. Following this, the experiment was carried out in a cyclic manner according to the scheme presented in figure 1 . Each cycle was initiated by a bedside blood glucose measurement followed by three minutes of rest for basal EEG monitoring. Subsequently, 30 ml of venous blood was drawn for measurement of plasma glucose, substrates, counterregulatory hormones, and renin-angiotensin system (RAS) hormones. Thereafter, auditory evoked potentials (AEP) were recorded, another bedside blood glucose was measured, and the CalCAP test was performed.
Finally, hypoglycaemic symptoms were rated according to the Edinburgh Hypoglycaemia Symptom Score Questionnaire. 11 A total of seven cycles were performed. After each of the first three cycles regular human insulin (Actrapid, Novo Nordisk, Bagsvaerd, Denmark) 0.075 U/kg + 0.075 U/kg + 0.15 U/kg or placebo injections were given subcutaneously in the abdominal wall (figure 1). In pilot studies this dosage scheme resulted in stable hypoglycaemia with nadir in the range between 2.5-3.0 mmol/L, which was the hypoglycaemic target in this study. After the sixth cycle, subjects were given 0.5 litre of apple juice and rested for 20 minutes before the last cycle was carried out.
Cognitive function tests
The Danish version of the abbreviated CalCAP 10 test battery was used in the study. This test consists of four different reaction time tasks with different complexity based on presentations of numbers on the computer screen: 1) a simple reaction time test where subjects are instructed to strike a key whenever a number is presented; 2) a choice reaction task with reaction only to a specific number; 3) a choice reaction task with reaction to presentation of two identical numbers in a sequence; and 4) a similar test with reaction to presentation of two consecutive numbers in a sequence. Performance of the two latter tests includes the use of working memory. From the test results the individual mean reaction times (MRT) for each test (MRT 1, MRT 2, MRT 3, and MRT 4) and the error rates (ER = percentage of false positive + false negative reactions) for the three choice reaction tests (ER 2, ER 3 and ER 4) were extracted. 
EEG and AEP

Figure 1
Schematic design of experimental sessions. AEP = auditory evoked potentials; CalCAP = California Computerised Assessment Package; EEG = electronencephalogram; * = or placebo.
stimulation paradigm consisting of more than 500 stimuli delivered with an attended: unattended ear ratio of 1:4. In order to maintain attention subjects were asked to count the number of stimuli given to the attended ear. Two different tones were used: 700 Hz (attended ear) and 350 Hz (unattended ear). The duration of each stimulus was 100 ms and the inter-stimulus interval was 280 ms. The AEP sweeps were extracted from the continuous EEG recordings based on trigger pulses stored on auxiliary channels on the EEG recorder. The difference in amplitude between time-averaged (230-255 ms) potentials of attended and unattended sweeps (odd-ball response) was calculated.
Biochemical analyses
Blood samples were collected on ice, centrifuged at 5 o C within 20 minutes and specimens were stored immediately after at -80 o C until analysis. Bedside blood glucose used for monitoring during the experiments was carried out by a HemoCue Analyser every 15 minutes. Plasma glucose used for evaluation of the hypoglycaemic challenge was measured enzymatically (COBAS INTEGRA, Roche, Basel, Switzerland).
Glucagon concentrations in plasma were measured with a radioimmunoassay directed against the C-terminus of the glucagon molecule (antibody code no. 4305), which mainly measures glucagon of pancreatic origin. 12 The measurement of plasma catecholamines was based on high-pressure liquid chromatographic separation of radioenzymatically labeled catecholamines. 13, 14 Plasma cortisol was measured using a commercial kit (DSL-2100, Diagnostic Systems Laboratories Inc., Webster, Texas). Serum growth hormone concentration was determined with a commercial fluoroimmunometric method (Delfia, Wallac, Finland) using two monoclonal antibodies against two separate antigenic determinants on the growth hormone molecule. Pancreatic polypeptide was measured by a sensitive and specific radioimmunoassay described previously 15 using antibody 146-5. The calibrator was synthetic human PP (Sigma, St Louis, MO, USA) and the tracer was synthetic human PP labelled with 125 I using iodogen.
Plasma concentration of ketone bodies (D-βhydroxybutyrate) was measured by a fluorometric method (Ascent analyser, Labsystems, Helsinki, Finland) and free fatty acids, glycerol, lactate and alanine were determined spectrophotometrically (Hitachi 912 autoanalyzer, Roche, Glostrup, Denmark). Plasma concentrations of renin and angiotensinogen were determined using the principle of antibody trapping 16 as modified by Millar et al. 17 Plasma angiotensin (Ang) II concentration was measured according to the method of Kappelgaard et al. 18 with the modification that Sep-Pac C18 (Millipore Waters) was used for plasma extraction. Plasma aldosterone concentration was measured using a commercial kit (DSL-8600, Diagnostic Systems Laboratories Inc., Webster, Texas).
Statistics
Responses are shown as mean (±SE) net responses (=placebo-corrected Δ-values) unless otherwise stated. The effect of hypoglycaemia was assessed by one-sample t-test of the area under curve (AUC) and differences between groups were analysed by unpaired t-tests and two-sided p-values <0.05 were considered significant. The SPSS software package (Version 11.0) was used for statistical calculations.
Results
Plasma glucose
Insulin administration resulted in a similar hypoglycaemic stimulus in both of the ACE groups with plasma glucose nadir of 2.7 (0.1) mmol/L (figure 2). This was also confirmed by the frequent bedside measurements (not shown). Recovery of blood glucose following ingestion of apple juice was similar in the two ACE groups with prompt rises to 4.8 (0.3) mmol/L. No decline in plasma glucose was observed following placebo injections in any of the groups.
Cognitive function
The baseline performance in all tests both in terms of reaction time and error rate was similar in the two ACE groups (table 1). During hypoglycaemia the group with high ACE activity deteriorated significantly in performance of the most complicated CalCAP tasks both with regard to speed and precision ( figure 3 ). Thus, MRT 3 and ER 3 deteriorated significantly (p=0.027 and p=0.020). A similar trend was observed for MRT 4 and ER 4 (p=0.088 and p=0.065). The maximum prolongation of MRT 3 and MRT 4 was 120 ms and 110 ms corresponding to a 25% and 22% increment ( figure 3c and d) . The maximum absolute increment in ER 3 and ER 4 was 4.8% and 4.3% corresponding to relative increments of 244% and 81% (figure 3e and f). The cognitive dysfunction in the high ACE group persisted even after normalisation of plasma glucose. In the group with low ACE activity, in contrast, cognitive function was not affected significantly by hypoglycaemia. The high ACE group deteriorated significantly more in performance of the most complex task compared to the low ACE group. Thus, in the high ACE group the ER 3 response was greater (p=0.016) and the MRT 3 response tended to be greater (p=0.054). There were no alterations during the experiments in MRT 1, MRT 2 or ER 2 in any of the two groups.
Auditive evoked potentials
There was no effect of hypoglycaemia on the difference between response to attended and unattended sweeps (odd-ball response) in any of the groups (not shown).
Hypoglycaemic symptoms
There was no difference in baseline symptom scores between the groups (table 1) . Both groups reported significant autonomic symptom responses during hypoglycaemia compared to placebo ( figure   4 ; low ACE group: p=0.036, high ACE group: p=0.003). The neuroglycopaenic and total symptom responses were significantly different from placebo in the high ACE group (p=0.02 and p=0.004) but only tended to be so in the low ACE group (p=0.074 and p=0.091). The autonomic and total symptom response were greater in the high ACE group than in the low ACE group (p=0.050 and p=0.031). Following normalisation of plasma glucose, autonomic and total symptom scores remained elevated in the high ACE group.
Hormonal counterregulation
Significant responses were observed for all counterregulatory hormones during hypoglycaemia ( figure 5 ). There were no differences in the catecholamine, glucagon or cortisol responses between the groups. The responses of growth hormone and pancreatic polypeptide in the high ACE group tended to be greater than in the low ACE group (p=0.065 and p=0.060). figure 6d ). The alanine response to hypoglycaemia did not differ from that to placebo ( figure 6e ). There were no significant differences between the two groups in magnitude of substrate responses.
Substrates
RAS activation
There were no significant alterations in plasma angiotensinogen concentrations during hypoglycaemia in any of the groups (figure 7a). Plasma renin activity rose in both groups (figure 7b), but the response was only significant in the high ACE group (p=0.034). No significant responses of serum Ang II or plasma aldosterone concentrations were observed ( figure 7c and d) .
Cardiovascular responses
The pulse pressure tended to increase in both groups, but no significant alterations in heart rate were recorded.
Discussion
This study demonstrates an association between high spontaneous serum ACE activity and cognitive dysfunction during hypoglycaemia in healthy humans. Subjects selected by high ACE activity developed significant cognitive impairment lasting even after restoration of euglycaemia. In contrast those selected by low ACE activity showed no detectable cognitive dysfunction during or after hypoglycaemia despite a similar hypoglycaemic stimulus that was significant as evaluated by the symptomatic and counterregulatory responses. The result is in accordance with the association of high rate of severe hypoglycaemia with elevated serum ACE activity consistently reported in independent type 1 diabetic cohorts [5] [6] [7] [8] and the association with the Dallele of the ACE genotype conferring high ACE activity reported in some 5, 6 but not in all 19 studies. We have recently identified two additional RASrelated risk factors for severe hypoglycaemia in type 1 diabetes: high plasma angiotensinogen concentration and presence of the A-allele of the 1675AT polymorphism of the Ang II subtype 2 receptor conferring low expression of this receptor. 20 This suggests that the effect of high ACE activity is mediated through increased RAS activity.
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A difference between the groups with high or low ACE activity could potentially occur in every aspect of the response to insulin or protection against hypoglycaemia: level of hypoglycaemia, magnitudes of hormonal responses, mobilisation of substrates, and cognitive performance during hypoglycaemia. To avoid interference with the spontaneous metabolism and substrate fluxes during hypoglycaemia that may be important for maintenance of cognitive function we applied a standardised subcutaneous insulin challenge without exogenous glucose supply instead of hypoglycaemic clamping methods with variable glucose infusion rates to maintain stable hypoglycaemia as used by most groups. [21] [22] [23] [24] If our approach had resulted in variable depth of hypoglycaemia it may have been regarded as a limitation of the study. However, we achieved a similar hypoglycaemic stimulus in the two groups with both standardised insulin dosage and glucose support (zero). Overall counterregulatory responses were comparable to those obtained in studies using clamp techniques. [21] [22] [23] [24] [25] Cognitive function during hypoglycaemia can be assessed by a variety of different tests and there is no generally accepted gold standard. 26 Although they do not provide a comprehensive evaluation of cognition, choice reaction tasks (but not simple reaction tasks) are established as sensitive and valid markers of cognitive decline during hypoglycaemia. 26 In accordance with this, there was no effect of hypoglycaemia on performance of the simple reaction time task in either ACE group, whereas in the most complex choice reaction task requiring the use of working memory, reaction time was prolonged by 25 per cent and error rate was more than doubled in the group with high ACE activity. We did not find any changes in the odd-ball response in the AEP although we studied the 230-255 ms interval reported by other groups to change during hypoglycaemia. 27 There are no previous studies addressing the relationship between spontaneous ACE activity and cognitive function during hypoglycaemia. However, data from some human studies support an association between high ACE or general RAS activity and poor function during hypoglycaemia. Thus, pharmacological blockade of ACE activity by ACE-inhibitor treatment has been reported to attenuate counterregulatory responses in terms of catecholamines 28 and adrenocorticotropic hormone (ACTH) 29 and to reduce the glucose infusion rate necessary to maintain glucose level in hypoglycaemic clamp studies in healthy subjects. 30 Together, these studies suggest a beneficial effect of ACE-inhibition on maintenance of metabolism during hypoglycaemia. The finding that Ang II receptor blockade results in reduced symptoms and counterregulatory responses in healthy subjects 31 suggests that the effect may be due to inhibition of RAS activity in general rather than of ACE activity. This is supported by a study reporting more intense symptoms and greater counterregulatory responses during a hypoglycaemic clamp in the standing position (in which the RAS is activated) compared with the supine position in subjects with type 1 diabetes. 32 The suggestion of both of these latter studies that a blocked 31 or inactive 32 RAS is associated with blunted symptomatic responses to hypoglycaemia is in accordance with the less pronounced symptomatic responses in the low ACE group in this study.
Experimental animal data show that high activity of the RAS increases brain vulnerability to interruption of fuel supply in conditions such as ischaemia and hypoxia. Thus, in vivo studies in rodents subjected to experimental stroke have shown that animals overexpressing angiotensinogen 33 develop increased infarction volume and that intracerebroventricular infusion of Ang II results in increased brain damage following exposure to hypoxia. 34 Knockout of the AT 1receptor gene or pharmacological blockade of the receptor, which like other components of the RAS is abundant throughout the brain, results in reduced infarction size 33 indicating that the effect of Ang II is probably mediated by this receptor.
An effect of the renin-angiotensin system on brain function during hypoglycaemia could be caused by an influence on either supply or demand of substrate or both. During experimental hypoglycaemia cerebral glucose supply is maintained by increased cerebral blood flow. 35 Increasing cerebral blood flow further pharmacologically during hypoglycaemia in healthy humans results in blunted epinephrine and hypoglycaemic symptom responses 36 probably as a result of enhanced substrate supply. The cerebral vascular response to hypoglycaemia might be blunted in subjects with high circulating ACE activity. In our study, lactate concentrations in the low ACE subjects tended to increase more than in the high ACE subjects during and after hypoglycaemia. As infusion of lactate conserves human brain function during hypoglycaemia 37 increased lactate supply may contribute to their superior maintenance of cognitive function during exposure to hypoglycaemia. On the other hand, the paracrine RAS, which is widely distributed within the brain, may influence the cerebral metabolism of substrates. 38 Thus, knockout of the Ang II subtype 1 receptor gene is associated with conservation of ATP in neurons exposed to ischaemia suggesting either reduced or more efficient metabolism. 33 In addition to suggesting a mechanism for the association between high ACE activity and risk of severe hypoglycaemia in type 1 diabetes, the result of this study may contribute to the explanation of the association between the Insertion allele of the ACE gene and superior human endurance performance capacity suggesting a beneficial effect of low ACE activity. 39 As our study shows that cognitive function declines significantly in healthy subjects with high ACE activity exposed to a moderate degree of substrate deficiency for a relatively short duration, ACE activity may be an important determinant of development of fatigue during endurance sports with exposure to severe and long-lasting fuel deprivation. Thus, the poorly understood phenomenon of central fatigue is regarded as an important limiting factor of endurance performance and has been attributed to impairment of brain function due to exhaustion or fuel starvation. 40 This phenomenon may well be influenced by ACE activity.
Further studies are warranted to verify our findings including studies during more profound hypoglycaemia and studies with type 1 diabetic subjects. Moreover, studies of the effect of treatment with ACE inhibitors and Ang II receptor antagonists (ARBs) on cognitive function during experimental hypoglycaemia are needed to evaluate whether these agents might have a role in prevention of severe hypoglycaemia. In this context, older registry-based studies have reported a controversial association between ACE-inhibitor treatment and severe hypoglycaemia 41 which was not present in a controlled trial. 42 A more recent cross-sectional study, on the other hand, reported a reduced rate of severe hypoglycaemia in patients treated with ACE-inhibitors or ARBs, compared to patients treated with other antihypertensives. 4 The study was funded by grants from The EFSD/ 
